SFMET

HGF/SF and MET in metastasis

 Coordinatore THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE 

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Ms.
Nome: Dawn
Cognome: Barker
Email: send email
Telefono: +44 1223 333543
Fax: +44 1223 332988

 Nazionalità Coordinatore United Kingdom [UK]
 Sito del progetto http://www2.mrc-lmb.cam.ac.uk/sfmet/index.html
 Totale costo 4˙141˙339 €
 EC contributo 2˙927˙008 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-04-01   -   2011-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Ms.
Nome: Dawn
Cognome: Barker
Email: send email
Telefono: +44 1223 333543
Fax: +44 1223 332988

UK (CAMBRIDGE) coordinator 0.00
2    CONSORZIO INTERUNIVERSITARIO RISONANZE MAGNETICHE DI METALLOPROTEINE PARAMAGNETICHE

 Organization address address: Via Luigi Sacconi 6
city: SESTO FIORENTINO
postcode: 50019

contact info
Titolo: Prof.
Nome: Ivano
Cognome: Bertini
Email: send email
Telefono: +39 055 4574272
Fax: +39 055 4574271

IT (SESTO FIORENTINO) participant 0.00
3    MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT

 Organization address address: ROBERT ROSSLE STRASSE 10
city: BERLIN
postcode: 13125

contact info
Nome: Manuela
Cognome: Adloff
Email: send email
Telefono: -94062204
Fax: -94062562

DE (BERLIN) participant 0.00
4    UNIVERSITA DEGLI STUDI DI TORINO

 Organization address address: Via Giuseppe Verdi 8
city: TORINO
postcode: 10124

contact info
Titolo: Prof.
Nome: Maria Flavia
Cognome: Di Renzo
Email: send email
Telefono: +39 011 9933343
Fax: +39 011 9933417

IT (TORINO) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

hgf    strength    antagonist    tumours    invasion    antagonists    signalling    met    molecular    nk    tumour    sf    human    receptor    cells    weight    cancer    metastasis    therapeutics    inhibitors    mechanism    shp    tissue   

 Obiettivo del progetto (Objective)

'The growth and motility factor HGF/SF and its receptor MET define a paracrine signalling system which controls the migration of several cell lineages in embryogenesis and tissue repair. In a large number of human tumours, cancer cells hijack HGF/SF and MET signalling in order to invade adjacent tissue and initiate metastasis. The evidence for this is strong, broad and consistent and highlights HGF/SF and MET as key effectors of tumour invasion and primary targets for therapy. This proposal has two objectives. The first is to understand the mechanism by which HGF/SF and MET cause tumour invasion and, specifically: - how local hypoxia induces MET over-expression in tumour cells and how the MET - WNT and the MET - chemokine pathways cooperate in metastasis. The second aim is to develop MET therapeutics. These will include: (i) a protein antagonist built from a fragment of the ligand known as NK1, (ii) low molecular weight MET antagonists and, (iii) inhibitors of SHP-2, a critical effector of MET signalling. NK1 will be engineered as a receptor antagonist on the strength of available crystal structures. Low molecular weight MET antagonists and SHP-2 inhibitors will be developed on the strength of: - the availability of recombinant forms of the target proteins, - suitable screening methodologies and, - the results of initial screens that have provided robust proof of principle for both approaches. The proposal thus builds on strong progress in participating laboratories on the structure and function of HGF/SF and MET and fulfils the three key criteria described in the call for proposal ‘Understanding and fighting metastasis’, namely: (i) it addresses a key mechanism of dissemination of human tumours, (ii) contributes to understanding the interplay between the tumour microenvironment (the source of HGF/SF) and tumour cells (the cells that express the MET receptor) and, (iii) has considerable prospects of delivering novel therapeutics for metastatic cancer'

Altri progetti dello stesso programma (FP7-HEALTH)

BIO-DRIM (2012)

Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation

Read More  

FAD (2008)

Fighting Aneurysmal Diseases

Read More  

T-CONTROL (2013)

Donor T Cells for Immune Control

Read More